EWING, NJ--(Marketwire - January 12, 2009) -
Highlighted Links |
http://www.dorbiopharma.com |
Under the terms of the agreement, DOR will sell 20,000,000 common shares together with a five year warrant to purchase up to 20,000,0000 shares of DOR common stock at $0.14 per share, for an aggregate price of $2,280,000 ($0.114 per share representing a premium to the trailing average of DOR's common stock closing prices over the last five days). The expiration date of the warrants will be accelerated if the Company's common stock meets certain price thresholds and DOR would receive additional gross proceeds of approximately $2.8 million if exercised.
"The New Year is off to an exciting start for DOR and its shareholders," stated Christopher J. Schaber, Ph.D., President and Chief Executive Officer of DOR. "With a strengthened balance sheet, we will be able to focus on beginning our confirmatory Phase 3 trial of orBec® while continuing to explore all partnering options with Sigma Tau. We look forward to building on our recent achievements and expect 2009 to be an eventful year."
The Company's common stock will be sold to an accredited investor in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The shares will not be registered under the Securities Act or any state securities laws, and the shares may not be offered or sold absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. In connection with the offering, DOR has agreed to file a registration statement under the Securities Act covering the resale of the shares purchased within 20 days of the closing of the transaction. This press release does not and will not constitute an offer to sell or the solicitation of an offer to buy shares and is being issued under Rule 135c under the Securities Act.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec® for the treatment of GI GVHD in 1H 2009. orBec® is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax™, has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.
For further information regarding DOR BioPharma, Inc., please visit the Company's website at www.dorbiopharma.com.
This press release contains forward-looking statements that reflect DOR
BioPharma, Inc.'s current expectations about its future results,
performance, prospects and opportunities. Statements that are not
historical facts, such as "anticipates," "believes," "intends," or similar
expressions, are forward-looking statements. These statements are subject
to a number of risks, uncertainties and other factors that could cause
actual events or results in future periods to differ materially from what
is expressed in, or implied by, these statements. DOR cannot assure you
that it will be able to successfully develop or commercialize products
based on its technology, including orBec®, particularly in light of the
significant uncertainty inherent in developing vaccines against bioterror
threats, manufacturing and conducting preclinical and clinical trials of
vaccines, and obtaining regulatory approvals, that its cash expenditures
will not exceed projected levels, that it will be able to secure
partnerships or obtain financing within the next nine months to meet
operating expenses and to conduct its upcoming confirmatory Phase 3 trial
of orBec®, that product development and commercialization efforts will
not be reduced or discontinued due to difficulties or delays in clinical
trials or due to lack of progress or positive results from research and
development efforts, that it will be able to successfully obtain any
further grants and awards, maintain its existing grants which are subject
to performance, enter into any biodefense procurement contracts with the US
Government or other countries, that the US Congress may not pass any
legislation that would provide additional funding for the Project BioShield
program, that it will be able to patent, register or protect its technology
from challenge and products from competition or maintain or expand its
license agreements with its current licensors, or that its business
strategy will be successful. Important factors which may affect the future
use of orBec® for gastrointestinal GVHD include the risks that: the FDA's
requirement that DOR conduct additional clinical trials to demonstrate the
safety and efficacy of orBec® will take a significant amount of time and
money to complete and positive results leading to regulatory approval
cannot be assumed; DOR is dependent on the expertise, effort, priorities
and contractual obligations of third parties in the clinical trials,
manufacturing, marketing, sales and distribution of its products; orBec®
may not gain market acceptance if it is eventually approved by the FDA; and
others may develop technologies or products superior to orBec®. These and
other factors are described from time to time in filings with the
Securities and Exchange Commission, including, but not limited to, DOR's
most recent reports on Forms 10-Q and 10-KSB. Unless required by law, DOR
assumes no obligation to update or revise any forward-looking statements as
a result of new information or future events.
Company Contact:
Evan Myrianthopoulos
Chief Financial Officer
(609) 538-8200
www.dorbiopharma.com
DOR BioPharma, Inc.
850 Bear Tavern Road, Suite 201
Ewing, NJ 08628